Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Benjamin

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Journal of Cancer Policy|November 2, 2023
Starting and stopping cancer drugs: The need for randomized trialsDavid J Benjamin, Vinay Prasad
Frontiers in Immunology|September 7, 2023
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapyDavid J Benjamin, Robert Hsu
Nature Reviews. Urology|April 28, 2022
Quality of life in sexual minorities following prostate cancer treatmentDavid J Benjamin, Arash Rezazadeh
Frontiers in Oncology|December 18, 2023
A narrative review of antibody-drug conjugates in <i>EGFR</i>-mutated non-small cell lung cancerRobert Hsu, David J Benjamin
The Lancet. Oncology|July 28, 2022
PI3K inhibitors in haematological malignanciesDavid J Benjamin, Vinay Prasad
The Lancet. Oncology|April 30, 2022
Accelerated approval requirements for lurbinectedinDavid J Benjamin, Vinay Prasad
Cancers|November 27, 2021
Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder CancerDavid J Benjamin, Yung Lyou
The Oncologist|September 8, 2023
Reevaluating Adjuvant Capecitabine for Resected Biliary Tract CancerDavid J Benjamin, Vinay Prasad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2022
Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?David J Benjamin, Misako Nagasaka
European Journal of Cancer (Oxford, England : 1990)|October 5, 2024
Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancerDavid J Benjamin, Vinay Prasad
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Journal of Cancer Policy|November 2, 2023
Starting and stopping cancer drugs: The need for randomized trialsDavid J Benjamin, Vinay Prasad
Frontiers in Immunology|September 7, 2023
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapyDavid J Benjamin, Robert Hsu
Nature Reviews. Urology|April 28, 2022
Quality of life in sexual minorities following prostate cancer treatmentDavid J Benjamin, Arash Rezazadeh
Frontiers in Oncology|December 18, 2023
A narrative review of antibody-drug conjugates in <i>EGFR</i>-mutated non-small cell lung cancerRobert Hsu, David J Benjamin
The Lancet. Oncology|July 28, 2022
PI3K inhibitors in haematological malignanciesDavid J Benjamin, Vinay Prasad
The Lancet. Oncology|April 30, 2022
Accelerated approval requirements for lurbinectedinDavid J Benjamin, Vinay Prasad
Cancers|November 27, 2021
Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder CancerDavid J Benjamin, Yung Lyou
The Oncologist|September 8, 2023
Reevaluating Adjuvant Capecitabine for Resected Biliary Tract CancerDavid J Benjamin, Vinay Prasad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2022
Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?David J Benjamin, Misako Nagasaka
European Journal of Cancer (Oxford, England : 1990)|October 5, 2024
Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancerDavid J Benjamin, Vinay Prasad
Pageof 9